Author: Editor

Mark Caulfield, MD from Genomics England and Queen Mary University, London, UK gives an overview of the 100,000 Genomes Project, which is about sequencing the genomes of patients with rare inherited diseases, cancer and infections. The focus is on transforming the National Health Service (NHS) making the UK a world leader in the application of genomic medicine to healthcare. Prof Caulfield explains the challenges associated with analyzing tissue from tumors. He further discusses a programme that sequenced 150 patients with chronic lymphocytic leukemia (CLL) and plans for working on acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and multiple myeloma…

Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY gives an overview of her talk on ‘How I use molecular genetics to guide treatment in AML’ held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), in Glasgow, Scotland. In the US, the standard of care in terms of molecular genetics for acute myeloid leukemia (AML) is to order FLT3, NPM1 and CEBP tests. According to Dr Roboz, it is now becoming more common to order up to 200 gene panels. In terms of treatment, FLT3 guides…

David Steensma, MD of the Dana-Faber Cancer institute, Boston, MA gives an overview of his talk on precision medicine for myelodysplastic syndromes (MDS) held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. Dr Steensma discusses how precision medicine can be interpreted differently and more specifically, what drug therapies could be targeted to which patients with MDS. Dr Steensma discusses what is being learned about the genetics of MDS and how to refine treatment algorithms in the future. He further talks about the discovery that molecular diagnostic testing…

Chng Wee Joo, MB, ChB, PhD, FRCP, FRCPath, FAMS from the National University Cancer Institute, Singapore gives an overview of his talk on the utility of next-generation sequencing (NGS) in multiple myeloma (MM) held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. According to Prof Chng, a lot of progress has been made in NGS but its clinical use in MM is not well established yet. There is great potential in helping to target treatment and understanding prognosis as well as drug resistance. Further, a key point…

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the 5-year disease-free survival, defined as relapse, secondary malignancy or death, of patients with node-positive and high-risk node-negative early breast cancer who omitted adjuvant chemotherapy based on an Oncotype DX® 21-gene Recurrence Score® result of 11 or less in PlanB, a prospective phase 3 trial evaluating the Recurrence Score® result. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, explains the rationale and design of PlanB, a prospective phase 3 trial evaluating the Oncotype DX® 21-gene Recurrence Score® result for defining a low-risk subgroup of breast cancer patients with node-negative disease and high-risk clinicopathological factors as well as patients with node-positive disease who could be treated with adjuvant endocrine therapy alone. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

This Expert Perspectives activity features the clinical faculty from a symposium held at the 2016 Annual Meeting of the Oncology Nursing Society sharing highlights from the symposium and additional relevant clinical commentary. Significant advances have elevated breast cancer care to new levels of success and complexity. In particular, for women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC), the availability of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor therapy is a notable recent advance. As such, clinicians who treat breast cancer need ongoing education on this topic to ensure safe and effective use of this therapy. Earn accreditation for…

In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve Patient Outcomes” symposium held during the 2016 Annual Meeting of the Oncology Nursing Society, Austin Kershner discusses how to council ER+ metastatic breast cancer patients on the safety expectations and side effects of CDK 4/6 inhibitors. Earn accreditation for this activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7208 © 2016 Imedex, LLC.

In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve Patient Outcomes” symposium held during the 2016 Annual Meeting of the Oncology Nursing Society, Meg Trewhitt Discusses how to council ER+ metastatic breast cancer patients on efficacy expectations for CDK 4/6 inhibitors.

In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve Patient Outcomes” symposium held during the 2016 Annual Meeting of the Oncology Nursing Society, Dr. Ruth O’Regan discusses the biological rationale, development history, and dosing and administration of CDK 4/6 inhibitors in the ER+ metastatic breast cancer setting. Earn accreditation for this activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7208 © 2016 Imedex, LLC.

Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, and President of the European Society for Blood and Marrow Transplantation (EBMT), talks about the a symposium hosted at the 2016 Annual Meeting of EBMT, held in Valencia, Spain, focusing on the role of proteosome inhibitors in multiple myeloma (MM). In the last 15 years, we have lived with the 1st generation proteosome inhibitors for the treatment of MM, mainly bortozemib. However, in the recent years the research community has developped 2nd generation proteosome inhibitors, such as carfilzomib and ixazomib. This symposium focused on the mechanistic aspects of these inhibitors in…

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, John Murray, a Nurse Clinician at the Christie NHS Foundation Trust, Manchester, UK, discusses the importance of information availabilty for patients. With the advent of the internet patients are becoming more empowered. By learning about different treatment options, their side effects, and ongoing clinical trials patients can make informed decisions and better cope with their disease.

Chiara Bonini, MD, from San Raffaele Scientific Institute, Milan, Italy, gives an overview of the ongoing randomised Phase III trial TK008 (NCT00914628), which looks at the ability of donor lymphoctyes to recognise and kill leukemia cells and the control of graft-versus-host-disease (GvHD) via the use of a suicide gene in high-risk leukemia patients who underwent haploidentical hematopoietic cell transplantation. The aim is immunoreconstitution, a reduced relapse rate and control of GvHD. According to Prof Bonini, the killing of the gene modified cells and the control of GvHD has been reported as efficient in several studies.

Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses open questions in the assessment of response in multiple myeloma (MM). According to Dr Paiva, we should see overall response rates of around 70-80% in a relapsed/refractory setting and complete remission (CR) rates of around 20-30%. In future, a deep response, including minimal residual disease (MRD) negativity, may be a goal for fit relapsed/refractory patients. Other areas that require research are biomarkers and ultra chemotherapy-resistant MRD cells. Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses the current status of novel treatments in multiple myleoma (MM). According to Dr Paiva, the last three years have seen important advances for transplant eligible and ineligible MM patients. There are two questions that need to be addressed: how to combine the new agents with the current backbone therapy and how to combine the various individual novel drugs. Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel, discusses why immunotherapy is his highlight from the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain. Prof Nagler explains the importance of chemotherapy in clinical practice at the moment but also, that it is a very crude treatment. Then he discusses the new developments in immunotherapy, such as monoclonal antibodies and chimeric antigen receptors (CARs) and their promise for the future of cancer therapy.

Ali Bazarbachi, MD, from the American University of Beirut, Beirut, Lebanon explains his research into the use of FLT3 inhibitors in acute myeloid leukemia (AML). FLT3 inhibitors are tyrosine kinase inhibitors and in the first-line treatment of AML combined with chemotherapy, they have shown a survival advantage. Further, they can be used in relapsed AML in transplanted and non-transplanted patients. The most promosing setting for FLT3 inhibitors is in maintenance therapy after allogeneic stem cell transplantation to avoid relapse. Prof Bazarbachi further discusses the implications of these results and the ongoing clinical trials in this area. According to Prof Bazarbachi,…

Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel, discusses the use of drugs and transplantation in acute leukemias. Prof Nagler describes how drug therapy and transplantation are used together in order to achieve the best outcomes for the patients. For example, with the help of the drugs, the mass of a tumor can be reduced pre-transplant, which in turn means, that less chemotherapy may be required. Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain.

Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of the safety and effectivness of virus-specific T cells and their use in transplant patients. According to Dr Leen, there is a lot of research focusing around the use of algorithms to help phyisicans choose the right product for their patients and the next step would be a registration trial. She further describes how referrals usually come from transplant physicians. In order to provide the virus-specific T cells to the patients, they require the HLA characteristics of the patient and the details of their infection. Recorded…

Ali Bazarbachi, MD, from the American University of Beirut, Beirut, Lebanon provides an overview of FLT3 mutations in acute myeloid leukemia (AML) at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain. FLT3 is a tyrosine kinase and FLT3 mutations are seen in over 30% of AML patients according to Prof Bazarbachi. FLT3 mutations are associated with a poor prognosis and currently, researchers are investigating the use of tyrosine kinase inhibitors to target FLT3 mutations.

Ivan Borello, MD from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Batlimore, MD discusses the highlights in immunotherapy and in particular CAR T-cells for multiple myeloma (MM) from the Myeloma 2016 meeting held in Boston, MA with Edward Stadtmauer, MD from the University of Pennsylvania, Philadelphia, PA, James Kochenderfer, MD from the National Cancer Institute, Bethesda, MD and Michael Hudecek, MD from the University of Würzburg, Würzburg, Germany. Prof Stadtmauer discusses his talk on the CD19 targeted T-cells and the rationale behind targeting tumors that are not expressing CD19. They further talk about the B-cell maturation antigen (BCMA) and…

Stephen Russell, MD, PhD from the Mayo Clinic, Rochester, MN discusses highlights from the session ‘Environment biology insights’ in multiple myeloma (MM) held at the Myeloma 2016 meeting in Boston, MA with Dirk Hose, MD from the University of Heidelberg, Heidelberg, Germany and Suzanne Lentzsch, MD, PhD from the Columbia University Medical Center, New York, NY. Prof Russell first highlights the talk by Madhav Dhodapkar from the Yale Cancer Center on monoclonal gammopathy of undetermined significance (MGUS). Dr Hose then discusses his talk on the evolution of MGUS to multiple myeloma (MM). According to Dr Hose, the main factors driving…

Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of the Cassiopeia trial on daratumumab in transplant eligible multiple myeloma (MM) patients. The trial compares bortezomib, thalidomide, dexamethasone (VTD) followed by stem cell transplantation, followed by two cycles of consolidation therapy with VTD with or without daratumumab (NCT02541383). The primary endpoint is stringent complete remission (CR). Within the same study, there is a second randomization with daratumumab maintenance for two years versus no maintenance. The goal is to show that the addition of daratumumab will improve the quality of response and therefore progession-free survival and…

Paul Richardson, MD from the Dana-Farber Cancer Institute, Boston, MA discusses his talk on ‘Perspectives on future paths to cure’ in multiple myeloma (MM) held at the Myeloma 2016 meeting in Boston, MA. Dr Richardson discusses monoclonal antibodies, proteasome inhibitors, immunomodulatory drugs (IMiDs), HDAC inibitors as well as the role of transplants. He first discusses daratumumab, which is considered a breakthrough drug in MM. While daratumumab is used in monotherapy, elotuzumab needs to be combined with proteasome inhibitors or IMiDs. Further isatuximab, which targets CD38, appears to very promising. In terms of the new proteasome inhibitors, Dr Richardson discusses ixazomib,…

Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY gives an overview of his talk on the applications of minimal residual disease (MRD) testing in multiple myeloma (MM) held at the Myeloma 2016 meeting in Boston, MA. Dr Landgren outlines how two years ago, around 30% of institutions conducted flow based MRD testing while now, it is 60%. He further discusses the work that remains to be done in this field. According to Dr Landgren, MRD has arrived in MM due to the various new therapies that are now available. In terms of applications for…

Nikhil Munshi, MD from the Dana-Farber Cancer Institute, Boston, MA gives an overview of the data presented on the Dana-Farber Cancer Institute (DFCI) genomics program in multiple myeloma (MM) at the Myeloma 2016 meeting held in Boston, MA. The summary of the DNA data shows many mutations whereby no single mutation is more frequent that 20%. The data provides information on potential new targets, such as in the RAS, RAF and p53 pathway. Further, there are multiple clones in myeloma, which change over time which means that genomic analysis at diagnosis may not be adequate. Moreover, Dr Munshi discusses the…

At the Myeloma 2016 meeting held in Boston, MA, Daniel Auclair, PhD, from the Multiple Myeloma Research foundation (MMRF) discusses highlights from the meeting for patients with Kenneth Anderson, MD from the Dana-Farber Cancer Institute, Boston, MA, Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ and Sagar Lonial, MD from the Winship Cancer Institute, Atlanta, GA. Prof Anderson highlights immune therapies and in particular, check-point inhibitors, CAR T-cell therapy and immunomodulatory drugs (IMiDs) such as pomalidomide and lenalidomide. According to Prof Anderson, the main message is that there are many immune therapies now and drug combinations will play…

Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA, discusses the mechanism of action of venetoclax and next steps for the drug in multiple myeloma (MM). Venetoclax is an inhibitor of BCL-2 and has recently been approved for the treatment of chronic lymphocytic leukemia (CLL). According to Prof Boise, only a small fraction of multiple myeloma patients appear to be sensitive to venetoclax and the next step is to find a marker that can identify those patients. Another area of research concerns drug combinations, i.e. finding drugs such as dexamethasone, that can be combined with venetoclax. Recorded at the…

Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of his talk on ‘Immunotherapy checkpoint inhibitor trials’ presented at the Myeloma 2016 meeting in Boston, MA. First, Prof San Miguel discusses the lenalidomide and pembrolizumab KEYNOTE-023 trial (NCT02036502). The treatment was well tolerated and the response rate was 76% for the overall population and 50% for the double refractory population. Then, he discusses the trial of pembrolizumab plus pomalidomide (NCT02289222); the response rate was 60% for the overall population and 50% for the double refractory population. Recorded at the Myeloma 2016 meeting held in…

Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium gives an overview of the mechanism of action of proteasome inhibitors. Prof Delforge gives a detailed outline of how the proteasome is targeted. He further discusses the different classes of proteasome inhibitors, i.e. the boronic acid derivatives (bortezomib, ixazomib), epoxyketone derivatives (carfilzomib, oprozomib)and salinosporamide derivatives (marizomib). Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Carlos Fernandez de Larrea, MD, PhD from the Hospital Clínic de Barcelona, Barcelona, Spain discusses the definition of complete remission (CR) in multiple myeloma (MM). The current definiton of CR requires a negative serum and IFE and less than 5% bone marrow plasma cells (BMPCs). However, two-thirds of patients with CR still relapse and the aim is to be able to identify those patients who are really cured. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

María-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain gives an overview of the challenges associated with assessing and treating smouldering myeloma. Smouldering myeloma is a heterogeneous disease and Dr Mateos explains how the difficulty in assessing whether a patient is at risk of progressing to symptomatic myeloma, can vary from case to case. She explains the use of the Mayo Clinic model and monitoring strategies in case of low, intermediate and high risk of progression to myeloma. For high risk patients, Dr Mateos suggests that in future, they will be offered an early treatment. Recorded at…

Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium gives an overview of the two trials on second generation proteasome inhibitors. First, Prof Delforge discusses the ENDEAVOUR trial (NCT01568866), which compared carfilzomib plus dexamethasone (Kd) with bortezomib plus dexamethasone (Vd). Progression-free survival doubled in the Kd arm compared to the Vd arm and further, the depth of response was superior in the Kd arm. Prof Delforge also discusses the occurence of side effects such as peripheral neuropathy and cardiovascular toxicity. Prof Delforge further discusses the ASPIRE trial (NCT01080391) comparing carfilzomib, lenalidomide and dexamethasone (CRd) vs lenalidomide and dexamethasone…

Thierry Facon, MD, PhD, from Hospital Claude Huriez, Lille, France provides an overview of the topics and sessions covered at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. Some of the areas covered at the meetings were the biology and genetics of the disease as welll as imaging techniques and minimal residual disease assessment. Prof Facon further discusses the approval of new drugs for multiple myeloma (MM), which include pomalidomide, panastinomab, ixazomib, elotuzumab and daratumumab. According to Prof Facon, it may be possible to cure patients with MM in future. He further discusses PD-1…

Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium discusses the role of bortezomib in relapsed/refractroy multiple myeloma (MM). Prof Delforge, discusses the various trials that showed the superiorty of the proteasome inhibitor bortezomib in terms of response and time to progression. According to Prof Delforge, bortezomib is an ideal backbone and is combined with dexamethasone alone, or dexamethasone and a third agent, for example chemotherapy or immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, pomalidomide. Bortezomib can further be combined with histone deacetylase (HDAC) inhibitors like vorinostat and panobinostat. Prof Delforge discusses trials results for the various combinations.…

Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, USA provides an overview of monoclonal antibodies and checkpoint inhbitors for multiple myeloma at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. Currently, two antibodies are approved for routine use in the USA: elotuzumab, which targets SLAMF7 and is combined with lenalidomide and dexamethasone, and daratumumab, which is currently approved as a single agent. Checkpoint inhibitors are another important class of drugs according to Prof Lonial. Several trials have been launched looking into nivolumab and pembrolizumab, which target PD-1, in combination with lenalidomide…

Paula Rodríguez, MD, PhD from the University Clinic of Navarra, Pamplona, Spain gives an overview of her talk on anticancer immunity in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Cancer cells have varied mechanisms to evade immune control and the basis of anticancer immunity is to disrupt these mechanisms. According to Dr Rodríguez, there are four approaches to disrupt these mechanisms: monoclonal antibodies, boosting the effector cells with adoptive therapy such as CAR T-cells, vaccination or using drugs like checkpoint inhibitors to overcome the immune suppression. Dr Rodríguez further…

Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France talks about the progress that has been made in treatment of multiple myeloma (MM). According to Prof Avet-Loiseau, in five years from now, it may be possible to cure around 50% of patients with MM with intensive therapy. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives an overview of his talk on the access to novel drugs in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Prof Harousseau argues that it is important to take into consideration, that several new drugs have been approved in recent years and life expectancy for patients has improved. He further discusses the issue of drug prices and the sustainability of healthcare systems as well as the strategies employed by various countries, such as Germany and France, to assess the…

Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses the impact of next-generation sequencing (NGS) on the treamtment of multiple myeloma (MM). First, NGS may be used to assess the prognosis for patients in future. It may also be used to identify molecular targets for individual patients and help physicians choose the right drug for their patient. According to Prof Avet-Loiseau, it may also be used for the assessment of minimal residual disease (MRD). Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Evangelos Terpos, MD, PhD, University of Athens, Athens, Greece discusses the open issues in the use of imaging techniques for the assessment of response in multiple myeloma (MM). One question concerns the MRI and how to better define complete response and further how often the MRI needs to be repeated. The same questions apply to PET-CT. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France discusses the role of the patient in the debate around the access to and affordability of novel drugs in multiple myeloma (MM). Prof Harousseau argues that patients should be aware of novel drugs and their benefit, which may not always be significant. He further argues that like doctors, patients should take into consideration the cost-effectiveness ratio and further, that patients should be involved in the evaluation of novel drugs. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Evangelos Terpos, MD, PhD, from the University of Athens, Athens, Greece discusses the limitations and challenges associated with using various imaging techniques to assess disease response in multiple myeloma (MM). According to Dr Terpos, with MRI it is possible to decide which patients to treat at diagnosis based on focal lesions while the PET-CT has the advantage of being able to better depict the living cells. Dr Terpos further discusses the benefits of diffusion weighted imaging MRI. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides an overview of the diagnostic criteria for smouldering myeloma. According to Dr Palumbo, hematological test plus a M-protein evaluation are the starting point and if indicated, this is followed by a bone marrow biospy and low-dose CT scan. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Carlos Fernandez de Larrea, MD, PhD from the Hospital Clínic de Barcelona, Barcelona, Spain discusses which techniques can be used to establish disease response in multiple myeloma (MM). For the detection of minimal residual disease (MRD), the most established technique is flow cytometry. In terms of imagng, clear criteria for the evaulation of PET/CT are required. Dr de Larrea further discussses the importance of standardizing the various techniques. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides treatment advice for smouldering myeloma. The key message, according to Dr Palumbo, is that today, smouldering myeloma is defined by the presence of 3g/dL of M-component and at least 10% bone marrow plasma cells. Further, Dr Palumbo discusses ultra high-risk smouldering myeloma and high-risk smouldering myeloma. Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides advice on how to treat multiple myeloma (MM). For patients younger than 75, autologous transplantation remains the standard of care and Dr Palumbo also suggests a three-drug combination induction therapy. For patients who are not eligible for a transplant, the advice is also a three-drug combination, which includes proteasome inhibitors plus an alkylating agent or a proteasome inhibitor plus IMiDs. For frail patients who are not transplant eligible and also have co-morbidities, Dr Palumbo suggests a two-drug combination therapy. Recorded at the 2016 World Congress on Controversies in Multiple…

In this introductory video on head and neck cancer, radiation oncologist Dr. Carryn Anderson of the University of Iowa defines head and neck cancers. Listen as Dr. Anderson explains typical symptoms and common causes. She also describes treatment standards and lists the customary members of your healthcare team. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France and Arnon Nagler, MD, from the Sheba Medical Center, Tel Hashomer, Israel, discuss the highlights from the second day of the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. First, Prof Nagler highlights the presentations that focused on the current situation in Asia and how therapies for multiple myeloma (MM) all around the world are improving. Prof Mohty also discusses the trials that are being run in China. Prof Nagler and Prof Mohty then discuss the Patient Advocate Meeting and the importance of the patient voice…

Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of immunomodulatory drugs (IMiDs) thalidomide, lenalidomide and pomalidomide for multiple myeloma (MM). According to Prof San Miguel, these drugs have reinforced the value of the immune system. The tumor cells use various mechanisms to evade immune system control, such as the PD-1/PDL-1 pathway. The monoclonal antibody pembrolizumab can release this particular break on the immune system. Prof San Miguel explains how preliminary data shows, that at the time of minimal residual disease (MRD) and relapse, the PD-1 is expressed on the T-cells and PDL-1 on…

Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of a prospective comparison on PET-CT and MRI in multiple myeloma (MM). The primary endpoint of the trial (NCT01309334) was to compare MRI and PET-CT in regard to the number of bone lesions at diagnosis and the secondary endpoint was to look at the prognostic impact of both imaging techniques. According to Prof Moreau, both techniques are equally effective at identifying the number bone lesions and PET-CT was able to predict progression-free survival (PFS). Prof Moreau argues that PET-CT is a very important imaging technique. Recorded…

Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives two message to stakeholders, such as pharmaceutical companies, the payers, such as healthcare providers, and doctors concerning the access to and affordability of novel drugs in multiple myeloma (MM). According to Prof Harousseau, the stakeholders should find a fair price for the drugs and act transparently. The payers should focus on the patient pathway and healthcare organization. Further, doctors should not only consider the efficacy but also the efficiency. His second message to the stakeholders, payers and doctors is to work together rather than against each other. Recorded at…

Paula Rodríguez, MD, PhD from the University Clinic of Navarra, Pamplona, Spain gives an overview of the two main PD-1 checkpoint inhibitors, nivolumab and pembrolizumab. A Phase I trial of nivolumab as a single agent for a group of hematological malignancies, showed an overall response rate of around 40% for diffuse large B-cell and follicular lymphoma (NCT02038933 and NCT02038946) and an overall response rate of 87% in Hodgkin lymphoma (NCT01592370). In multiple myeloma (MM), nivolumab as a single agent only achieved a stabilization of the disease and according to Dr Rodríguez, these drugs need to be combined in MM. Dr…

Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium provides an overview of the approval of proteasome inhibitors in relapsed/refractory multiple myeloma (MM) since 2003. Prof Delforge first discusses bortezomib, which was first approved by the US Food and Drug Administration (FDA) in 2003 and later, was approved for the use as upfront therapy in Europe and the US. Based on the success story of bortezomib, second generation proteasome inhibitors such as carfilzomib in combination with lenalidomide and dexamethasone, have been approved. Ixazomib, an oral proteasome inhibitor, has also been approved. Recorded at the 2016 World Congress on…

Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses his talk on prognostic factors in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Prof Avet-Loiseau, it is important to categorize the prognostic factors. Some prognostic factors, such as age and co-morbidities, are related to the patient. He further discusses prognostic factors related to the tumor clone, such as cytogenetics, and prognostic factors that are only identified after treatment, i.e. response to treatment. Prof Avet-Loiseau argues that in light of minimal residual disease (MRD)…

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Alessandro M. Vannucchi discusses the use of novel agents and combination therapies in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Nicolaus Kröger discusses the influence of mutational status on the timing, outcome and post-transplant management of patients with myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Mary F. McMulllin discusses how to manage side effects of JAK inhibitors in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Srdan Verstovsek provides an update on several JAK inhibitors in development for use in the treatment of myelofibrosis (MF). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Eilliot Winton examines whether there is any real clinical utility in utilizing mutation-based risk stratification approaches in the treatment of patients with myelofibrosis. Earn accreditation for a related activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Theo De Witte discusses novel strategies to prevent relapse of myelodysplastic syndromes (MDS) after allogeneic transplantation has been performed. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Michael Pfeilstöcker discusses newer therapeutic agents for use in the treatment of myelodysplastic syndromes (MDS) when hypomethylating agents (HMAs) fail. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Martin Jädersten provides an update on the use of erythropoiesis-stimulating agents and other growth factors in the treatment of low-risk myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Fabio Efficace discusses quality of life as a treatment goal in myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Torsten Haferlach discusses whether mutational profiling in patients with myelodysplastic syndromes (MDS) is ready for everyday use in the clinic. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Ruben A. Mesa discusses the pros and cons of therapy for “early” myelofibrosis. Earn accreditation for a related activity at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Gunnar BirgegÃ¥rd discusses what we have learned so far regarding the use of JAK inhibitors in the treatment of essential thrombocythemia (ET) and polycythemia vera (PV). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Jean-Jacques Kiladjian provides and update on long-acting interferons for the treatment of myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Michael Kroll discusses the diagnosis and treatment of splanchnic vein thrombosis and myeloproliferative neoplasms (MPN).

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Tiziano Barbui discusses the updated World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Rajko Kuec discusses the interplay of somatic and germline variants in myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Marie-Caterine Le Bousse-Kerdilès discusses cytokines, cells, and inflammation in myeloproliferative neoplasms (MPN). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Mario Cazzola discusses somatic mutations of RNA splicing machinery in myelodysplastic syndromes (MDS). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Carol Gambacorti-Passerini discusses the genetic basis of atypical chronic myeloid leukemia (CML). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Eric Solary discusses the genetic basis of chronic myelomonocytic leukemia (CMML). A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

This discussion between the chairs of the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes” provides a summary of the most intriguing and clinically applicable topics and data, outlines key learning points, and reinforces the take-home messages from the Congress. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Alessandro M. Vannucchi argues that early-stage myelofibrosis should be treated. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Paola Guglielmelli discusses the clinical benefit of JAK2 inhibitors in patients with myeloproliferative neoplasms. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Franscisco Cervantes discusses emerging JAK2 inhibitor combination treatment strategies for patients with myelofibrosis. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Mario Cazzola argues that early-stage myelofibrosis should be not treated but should be observed. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7212 © 2016 Imedex, LLC.

Metastatic Colorectal Cancer” symposium, Eric Van Cutsem discusses the emerging treatment options for metastatic colorectal cancer patients in the late-line setting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7200 © 2016 Imedex, LLC.

In this presentation from the “Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer” symposium, Dr. Howard S. Hochster discusses the management of adverse events associated with third-line treatments for metastatic colorectal cancer. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7200 © 2016 Imedex, LLC.

This discussion presents a discussion between world-renowned thought leaders Axel Grothey, Howard Hochster, and Eric Van Cutsem, who elucidate the effective implementation of new late-line CRC treatments in the clinical setting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7199 © 2016 Imedex, LLC.

In this webcast, Dr. David P. Steensma discusses the most pertinent information presented on leukemia and myeloid disorders during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this webcast, Dr. John P. Leonard discusses the most pertinent information presented on lymphoma during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this webcast, Dr. Robert Z. Orlowski discusses the most pertinent information presented on multiple myeloma during the 2016 Great Debates and Updates in Hematologic Malignancies meeting. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

Advancements in breast cancer care continue to rapidly evolve and the San Antonio Breast Cancer Symposium (SABCS) is the premier annual forum for exchange of new scientific and clinical information. However, not all healthcare professionals have the opportunity to attend this meeting and even those that do attend often can benefit from taking a deeper dive into the relevance of the data in a smaller venue in which more intimate faculty and peer interactions can take place. This is the role of the annual Best of San Antonio – Breast Cancer: Bench to Bedside meetingto help practicing clinicians interpret the…

Polycythemia vera (PV) is characterized by erythrocytosis, thrombocytosis, and/or leukocytosis with a broad-range of disease-related symptoms that impact the overall health and everyday quality of life of patients. The identification of the high frequency JAK2V617F mutation in patients with PV defines a molecular target for therapeutic intervention. This interactive case-based activity, is designed to complement, accelerate, and reinforce application of knowledge and skills amongst healthcare professionals interested in optimal management strategies for patients with PV. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7194 © 2016 Imedex, LLC.

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen receptor-positive (ER+) metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for this use. This activity discusses the ongoing and planned clinical trials for abemaciclib and ribociclib in ER+ metastatic breast cancer, as well as the future implications for this class of agents in this patient population. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7171 © 2016 Imedex, LLC.

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen ER+ metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for breast cancer. This activity discusses clinical data on the efficacy and safety of the FDA-approved CDK 4/6 inhibitor, palbociclib, in combination with letrozole in ER+ metastatic breast cancer. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7170 © 2016 Imedex, LLC.

The cyclin-dependent kinase (CDK) pathway is critical to cell cycle entry. In many tumor types, including breast cancer, there is dysregulation of this pathway. This activity describes the rationale and mechanism for inhibiting this dysregulated pathway in estrogen receptor-positive (ER+) metastatic breast cancer using selective CDK 4/6 inhibitors. A continuing education program related to this video is offered at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7169 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Paul Baas discusses updates in the systemic treatment of pleural mesothelioma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Elisabeth Quoix discusses the optimatl treatment of elderly patients with non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Maurice Perol discusses the targeting of angiogenesis for the treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses the maintenance paradigm for the treatment of non-squamous non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses the first- and second-generation ALK inhibitors for the treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Rafal Dziadziuszko discusses strategies for overcoming KRAS mutations. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses extreme rare mutations in lung cancer (ROS1, TRK, HER2) and the treatment opportunities available for them. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Nicholas Girard discusses the mechanisms of resistance to EGFR TKIs and new treatment strategies for combating this resistance. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Guilio Rossi discusses the an algorithm for molecular testing of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Gosney discusses the inherent challenges faced by the pathologist in the era of personalized medicine. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses response criteria and kinetics with the use of immunocheckpoint inhibitors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses how biomarkers predict the clinical activity of immunocheckpoints. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. David Waller argues that surgery is the treatment of choice for Stage 1 non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Umberto Ricardi argues that steretactic body radiation therapy (SBRT) is the treatment of choice for Stage 1 non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Vansteenkiste discusses the current status of adjuvant thereapy for the treatment of non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Richard Booton discusses the use of endobronchial and other techniquces to opmize the diagnosis and treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses new proposals for a new TNM classification for lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Klaus Irion discusses the use of diagnotics for the staging of lung cancer including the use of functional imaging and volumetric assessment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. John P. Leonard argues that watch and wait may still be utilized in cases of follicular lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michael E. Williams argues that “watch and wait” should not be utilized in the treatment of follicular lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Andrew M. Evens discusses the latest in the initial management of Hodgkin lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Morton Coleman argues that one should not utilize surveillance imagine for diffuse large b-cell lymphoma (DLBCL) patients in remission. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michell R. Smith argues that we should utilze surveillance imaging for diffuce large b-cell lymphoma (DLBCL) patients who are in remission. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Tracy Batchelor discusses the latest updates in primary CNS lymphoma management. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jonathan Friedberg argues that young paitnts with mantle cell lymphoma (MCL) should not be treated aggressively. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Brad S. Kahl argues that young patients with mantle cell lymphoma (MCL) should be treated aggressively. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Anas Younas discusses immune checkpoint inhibitors in lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard I. Fisher argues that R-CHOP should be utilized to treat patients with ABC-type diffuce large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Pierluigi Porcu argues that allogeneic stem cell transplant is the best approach for relapsed T cell lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Rafael Bejar discusses the promises and pitfalls in using molecular testing in the diagnosis of myelodysplastic syndromes (MDS). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Selina M. Luger argues that hypomethylating agents should be used with caution in lower-risk patients with myelodysplastic syndromes (MDS). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the management of chronic myelomonocytic leukemia (CMML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben A. Mesa discusses combination therapy with JAK2 inhibitors in the treatment of myeloproliferative neoplasms (MPN). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Sarah Nikiforow discusses the diagnosis and management of hemophagocytic lymphohistiocytosis (HLH). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Kenneth A. Bauer discusses the reversal of newer anticoagulants. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the diagnosis and management of atypical chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Racdich discusses practical advices for the molecular monitoring of chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Radich discusses at what point tyrosine kinase inhibitors can be stopped in the treatment of chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul Barr argues that the optimal treatment for chronic lymphocytic leukemia (CLL) patients with a 17p deletion is the use of a novel agent. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jacqueline Barrientos argues that ibrutinib is the optimal treatment for chronic lymphocytic leukemia (CLL) patiens with a 17p deletion. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Timothy Call discusses the clinical considerations for the use of oral targeted therapies in chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard R. Furman argues that CR and MRD negativity is no longer required for treatment of CLL in the era of novel agents. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that the best multiple myeloma salvage therapy is KRD. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the best multiple myeloma salvage therapy is novel therapy. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that upfront transplant should no longer be considered a standard of care in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky argues that high risk myeloma should not be treated differently. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that high risk myeloma should be treated differently. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the standard induction regimen for myeloma is RVD. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky discusses the use of monoclonal antibodies for the treatment of multiple myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses novel approaches to trial design in the era of molecular subtyping. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Karen T. Brown argues that ablation is the optimal treatment of localized hepatocellular carcinoma (HCC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that the optimal treatment of localized hepatocellular carcinoma (HCC) is either resection or transplant. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is the optimal chemotherapy backbone for targeted agents in pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is the optimal chemotherapy backbone for targeted agents in pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that chemotherapy alone is the preferred treatment for borderline, resectable pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt argues that epirubicin and other anthracyclines still have a role to play in the treatment of GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. David H. Ilson argues that epirubicin and other anthracyclines no longer have a place in the treatment of GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that the optimal pre-operative therapy for esophagus and GE junction cancers is chemotherapy alone. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses the molecular subtyping/profiling of upper-GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016” Dr. James C. Yao argues that bevacizumab cannot treat pancreatic neuroendocrine tumors (pNET). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Diane Reidy-Lagunes argues that everolimus does not have a role in the treatment of carcinoid tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. James C. Yao argues that everolimus has a role in carcinoid tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Mark Andrew Dickson discusses the management of GIST tumors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael J. Hall discusses genetics in gastrointestinal cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Luis A. Diaz discusses the use of liquid biopsies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses novel therapies for gastrointestinal malignancies beyond immunotherapy. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that biomarkers beyond MSI cannot direct immunotherapy in gastrointestinal malignancies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt discusses inflammation in colorectal cancer (CRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that TAS-102 followed by regorafenib is the preferred salvage therapy for metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that the preferred salvage therapy for metastatic colorectal cancer (mCRC) is regorafenib followed by TAS-102. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that borderline-resectable liver metastasis in RAS wild-type colorectal cancer (CRC) should be treated with a chemo doublet with EGFR inhibitor. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that borderline-resectable liver metastasis in RAS wild-type colorectal cancer (CRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that radioembolization of colorectal cancer (CRC) liver-limited metastases is not ready for use in the first line. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that radioembolization of colorectal cancer (CRC) liver-limited metastases is ready for use in the first line. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that there is no optimal first-line therapy sequence in metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that there is an optimal sequence for first-line therapy in metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that biomarkers do not have a role in the adjuvant setting for colorectal cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses the use of biomarkers for colon cancer treatment selection. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Charles B. Simone examines novel forms of radation delivery, and whether technology can trump biology in the treatment of disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass arguest that a trimodality approach is preferred for the treatment of locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski proposes that a bimodality approarch is preferential for the treatment of locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski discusses whether or not the choice of systemic agents or their sequencing makes a different in combined modality therapy for locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass discusses the mangement of the mediastinum and other surgical issues. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentatino, Dr. Gerard A. Silvestri outlines his perspective on the updated TNM classifications for malignant tumors, and expounds upon whether there is a role for histology of markers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology” Dr. Laura Jean Bierut examines current strategies for curtailing smoking addiction. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Benjamin Levy queries whether liquid biopsy will replace conventional tissue-based sampling. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. William K. Evans discusses the current cost and efficacy of managing non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sven de Vos disuccese new agents for use in the treatment of recurrent follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg argues against the use of maintenance rituximab for the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Gilles Salles argues that maintenance rituxumab should be used in the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Thomas E. Witzig discusses how he sequence therapy in the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jia Ruan examines the best approach to the initial therapy of peripheral t-cell lymphoma (PTCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presenation, Dr. Kami Maddocks discusses who should get what for upfront therapy of mantle cell lymphoma (MCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Adam M. Petrich discusses the best approach to treat double hit/double protein expression diffuse large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John P. Leonard discusses the hurdles to using cell of origin in the classification and treatment of diffuse large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Laurie H. Sehn discusses the best approach to limited stage diffuse large b-cell lymphoma (DLBCL), and whether that includes radiation. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Randy Gascoyne discusses the future of lymphoma pathology in the era of tumor profliing. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg discusses the highlights from the 2015 International Conference on Malignant Lymphoma, held in Lugano Switzerland. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete responses (CRs) in patients with chronic lymphocytic leukemia (CLL) following long-term treatment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve M. Ansell discusses the use of immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien argues that there is no value to the use of brentuximab vedotin as consolidation therapy following auto-SCT in Hodgkin Lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies” Dr. Robert W. Chen argues that there is value to using brentuximab vedotin as consolidation therapy shorlty following auto-SCT in Hodgkin Lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jeremy Abramson argues that chemotherapy-based regiments are the preferred second-line approach to induce lymphoma remission prior to stem cell transplant (SCT). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Allison Moskowitz argues that single-agent brentuximab is the best second-line approach to induce lymphoma remission prior to stem cell transplant (SCT). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Giorgio Inghirami discusses whether or not we can use patient-derived xenografts to assess new lymphoma therapies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Irene M. Ghobrial discusses why Waldenstrom’s and myeloma change from monoclonal gammopathy of undetermine significane (MGUS) to active disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Esteban Braggio discusses how useful genomics is in the clinical practice, with regard to the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien disccusses patient selection criterion for allogeneic transplant as treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John Allan discusses the risks, predictors, and treatment of Richter’s Syndrome. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jennifer R. Brown discusses whether the incidence of familial chronic lymphocytic leukemia (CLL) is increasing. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman elucidates the different between the various techniques of using CAR-T cells for the treatment of chronic lymphocytic leukemia (CLL) A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Mitchell R. Smith discusses when and how to use FCR and BR in the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve Coutre discusses tyrosine-kinase inhibitors (TKIs), apoptotic enhancers, and other small molecules in the pipeline for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman discusses risk assessment in the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kanti Rai discuses the most recently approved tyrosine-kinase inhibitors (TKIs) for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Neil Kay discusses the targeted inhibition of signal molecules as a novel therapy for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kenneth C. Anderson discusses new paradigms and therapies for the treatment of relapsed/refracory myeloma. He discussesthe use fo small molecules and monoclonal antibodies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Guentehr Koehne examines whether there is a role for allotransplant in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sundar Jagannath argues against maintenance therapy in the myeloma setting. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo argues in favor of the use of immunomodulatory drugs (IMiDs) for the maintenance of myeloma patients. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson argues that myeloma patients should be maintained with proteasome inhibitors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Tomer Mark argues that it is not necessary for patients to achieve a complete remission (CR) and minimum residual disease (MRD), and that transplant is therefore unnecessary. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Ajai Chari argues that it is necessary for patients to achieve a complete remission (CR) and minimum residual disease (MRD), and that transpant facilitates this. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo discusses the best treatment options for transplant-ineligible myeloma patients, and whether those comprise two, three, or four drug regimens. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. David Roodman discusses the advances in both biology and the treatment of myeloma bone disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this abstract presentation, Dr. Paul G. Richardson discusses the results of a mutlicenter Phase 2 trial on the use of ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple meyloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Renier J. Brentjens discusses the latest information on CARS and “armored” CARS as an immunological t-cell treatment of cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jatin J. Shah discusses whether high-risk myeloma should be treated differently and how one should do so. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. C. Ola Landgren examines whether minimum residual disease (MRD) is a necessary clinical tool of evaluation in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson discusses B-cell maturation antigen: a new biomarker for B-cell malignancies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP

Carlos Fernandez de Larrea, MD, PhD from the Hospital Clínic de Barcelona, Barcelona, Spain gives an overview of his talk on response assessment in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. According to Dr de Larrea, the response assessment in MM is crucial. It is important to establish whether a patient has achieved complete remission (CR) and to identify patients who are relapsing or progressing after different lines of treatment. Dr de Larrea further discusses the various techniques used to assess response, such as electrophoresis in serum and urine…

Do I need head and neck specialists for my cancer? Patient Power Founder and Host, Andrew Schorr, discusses this question with Head and Neck Oncologist Dr. Faye Johnson at MD Anderson Cancer Center. Although this question may seem obvious, Dr. Johnson stresses the importance of building a team that are head and neck oncology experts for the best possible rehabilitation and support. This team should include oncology, radiology, surgery, pathology, audiologist and/or speech therapy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

What are the targeted and less toxic treatments for head and neck cancers? Patient Power Founder and Host, Andrew Schorr, interviews Head and Neck Oncologist, Dr. Faye Johnson of The University of Texas MD Anderson Cancer Center in Houston. Dr. Johnson discusses four promising areas of targeted research in head and neck cancers, including immunotherapy and HPV. Dr. Johnson stresses that targeted therapies are best found in clinical trials and shares options on how patients can get connected. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on…

What exactly is MRD? Who should be tested? From the Myeloma 2016 meeting in Boston, Dr. Ola Landgren from Memorial Sloan Kettering Cancer Center explains MRD and what patients should be tested. He goes on to discuss how MRD and other diagnostic tests are being used by doctors in myeloma care, as well as updated guidelines for testing provided by the International Myeloma Working Group (IWMG). Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

How much of a difference in counts can you expect to see if you have blood drawn and processed at different labs? In this Ask the Expert segment, MPN expert Dr. Naveen Pemmaraju answers this question from viewer, Cindy. Dr. Pemmaraju discusses the variation in labs and offers tips to track your results, following trends versus the results of a single test. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Is stem cell transplant a viable treatment option? How long should maintenance therapy last? From the Myeloma 2016 meeting in Boston, myeloma expert Dr. Thomas Martin from UCSF Medical Center answered these questions and more related to myeloma treatment. He goes on to discuss new and upcoming myeloma treatments as well as the important role that research plays. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient Power Founder and Host, Andrew Schorr, discusses cancer screening with MD Anderson Cancer Centers Head and Neck Surgeon and Specialist, Dr. Erich Sturgis. Dr. Sturgis details the benefits of screening, particularly with the HPV vaccination. Screening allows specialists to identify cancer early enough in the process to increase the patients chance of successful treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

How do I manage my cancer pain? Patient Power Founder and Host, Andrew Schorr, interviews MD Anderson Cancer Center’s pain management specialist, Dr. David Hui. Dr. Hui has devoted his career to helping cancer patients find relief from their pain. Listen as he describes various types of pain and explains how to best manage your care and seek relief. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2016 World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland, Paul Richardson, MD, from the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA gives an overview of his talk on the latest advances in the clinical management of relapsed/refractory multiple myeloma (MM). He discusses several drugs that have been recently approved by the FDA in the US, namely pomalidomide, carfilzomib, the HDAC inhibitor panobinostat, elotuzumab, daratumumab, and ixazomib, which is the first oral proteasome inhibitor. According to Dr Richardson, these new drugs have had a dramatic effect on clinical management due to their novel…

At the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland. Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ gives an overview of a session on what the most appropriate approach to treating patients with relapsed myeloma. One of the key messages is the importance of using multiple drugs for treating multiple clones of the disease, according to Dr Stewart. He further discusses the combination of lenalidomide and dexamethasone as a backbone of carfilzomib, ixazomib and elotuzumab. According to Dr Stewart, randomized trials show that the combination…

What causes lung cancer? Can it be passed on genetically? Lung cancer experts Dr. George Simon of MD Anderson Cancer Center and Dr. Rebecca Heist of Harvard Medical Center discuss various common causes of lung cancer, including chemicals, pesticides and radon exposure. Dr. Simon concludes with screening options, including a new alternative to low-dose CAT scans. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

In this Ask the Expert segment, Patient Power community member, Peggy, wrote, How strong of a connection is there between long-term use of Jakafi and non-melanoma skin cancer? Should a patient quit taking medication? MPN expert Dr. Naveen Pemmarju of MD Anderson Cancer Center responds with a discussion of a journal article and goes on to stress the importance of vigilance and monitoring.

As part of Patient Powers coverage of Myeloma 2016, several renowned multiple myeloma experts joined together to discuss what they learned at the meeting. Drs. Ken Anderson, Keith Stewart, Noopur Raje and Sagar Lonial, discuss how the Myeloma 2016 meeting fosters collaboration among myeloma researchers, from all over the world. The experts discuss new discoveries, genetics, combination therapies, as well as how technological changes are allowing increasing the pace of advances in the field. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Anna Schuh, MD, PhD, from the University of Oxford, UK, gives an overview of her talk on the advances in the molecular stratification of chronic lymphocytic leukemia (CLL). The focus of the talk was to make sense of the biological and clinical heterogeneity of CLL patients. The fludarabine, cyclophosphamide and rituximab (FCR) therapy is still the standard of care frontline treatment and while data shows that many patients respond very well or have even shown to be cured, around 25% of patients will relapse within the first two years of having received chemoimmunotherapy according to Dr Schuh. Molecular markers may…

Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY gives an overview of the case studies on chronic lymphocytic leukemia (CLL) he presented at the 36th World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland. In the first case study, he discusses the use and side effect profiles of ibrutinib as well as idelalisib and rituximab. Dr Zelenetz also addresses the management of the side effects in his first case study. In the second case discussed, Dr Zelenetz discusses how the response to an alternative kinase inhibitor after progession is not very favorable.…

In this Ask the Expert video segment, multiple myeloma expert Dr. Jatin Shah of MD Anderson Cancer Center responds to a question about the reason why patients on multiple myeloma maintenance therapy are are advised to avoid antioxidants, particularly on medication day. Listen as Dr. Shah explains why high doses of vitamin C and green tea, as well as potential other antioxidants, are not recommended for patients on certain maintenance therapies. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

With all of the advances in cancer research, where does the field of prostate cancer stand? Andrew Schorr, Patient Power Founder, speaks with genitourinary clinician and researcher, Dr. Russell Szmulewitz, about the latest prostate cancer updates. Dr. Szmulewitz is very hopeful based on hormone therapies, current medications, and the climate of collaboration among international researchers. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

This was my talk at the University of Minnesota’s Masonic Cancer Center Seminar Series on May 10, 2016. I review translational approaches to cancer research, areas of cancer research that should be reassessed, and novel approaches to strategies that can be used in the lab to address clinically relevant questions in oncology. More information on my laboratory research and clinical work can be found on my UMN website: https://www.dom.umn.edu/divisions/hematology-oncology-and-transplantation/lou-lab

Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses current developments in myeloproliferative neoplasms (MPNs) at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) held in Glasgow, Scotland. According to Dr Mesa, it is a very exciting time for MPNs as new JAK inhibitors such as pacritinib and NS-018, anti-fibrosing agents such as PRM-151 as well as telomerase inhibitors such as imetelstat, are being developed.

Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA discusses how to manage adult myeloproliferative neoplasm (MPN) patients at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. An understanding of the patients’ risk, molecular features and their symptom burden is key to assessing their treatment options. Dr Mesa further discusses the prevention of vascular events through the use of aspirin and cytoreduction.

Ruben Mesa, MD, from the Mayo Clinic, Scottsdale, AZ, USA provides an overview of his talk on individualizing care for myeloproliferative neoplasm (MPN) patients held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. The focus is on understanding the indvidual patient’s disease burden and risk for molecular features and devising a plan for the patient that includes the prevention of vascular events and the avoidance of disease progression. Dr Mesa also discusses some of the key considerations that need to be taken into account for each patient,…

Peter Hillmen, MD, PhD, from St. James’ University Hospital, Leeds, UK gives an overview of the RESONATE-2 trial (NCT01722487), a randomized Phase III trial of ibtrutinib in chronic lymphocytic leukemia (CLL). The trial compared inbrutinib to chlorambucil and showed a significant improvement in progression-free survival (PFS), which was the primary endpoint, and further an overall survival (OS) advantage for patients on the ibrutinib arm. Overall, ibrutinib was well tolerated according to Prof Hillmen. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK discusses the potential benefit of a higher dose of daunorubicin for a sub-group of acute myeloid leukemia (AML) patients with the FLT3-ITD mutation. This study was conducted as part of the AML17 trial and the abstract was presented at the 2016 World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland. Patients were randomized to receive two different doses of daunorubicin at induction therapy. Prof Russell discusses the initial report, which showed that there was no advantage to using the higher dose of daunorubicin. However, further…

Gilles Salles, MD, PhD, from South Lyon Hospital Complex, Lyon, France discusses the management of patients with follicular lymphoma in the first-line and relapsed setting. Prof Salles outlines the different treatment approaches for patients with limited stage and extended stage disease. For example, patients with limited stage disease may receive radiation therapy and for patients with a high-tumor burden, the standard of care has been chemotherapy plus an anti-CD20 such as rituximab. Prof Salles further discusses the option of a chemotherapy-free approach and the various options in the relapsed setting. Recorded at the 2016 Annual Meeting of the British Society…

Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK talks about new and emerging drug targets in acute myeloid leukemia (AML). Prof Russell discusses the FLT3 mutation, which is one of the most established targets and has been a focus of research for several years, acute promyelocytic leukemia (APL), as well as the IDH1, IDH2 and NPM1 mutations. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

Gilles Salles, MD, PhD, from South Lyon Hospital Complex, Lyon, France provides an overview of his presentation on ‘chemo-free’ in follicular lymphoma held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), in Glasgow, Scotland. Prof Salles outlines the limitations of chemotherapy and the reasons why he supports a ‘chemo-free’ approach. He argues that chemotherapy is not curative and that agents that can modify the microenvironment, may be successful at managing the disease. For example, monoclonal antibodies such as anti-CD20, either alone or when combined with chemotherapy, can improve the survival…

Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the tolerability of monoclonal antibodies. According to Prof Martin, monoclonal antibodies are well tolerated, however, at the first infusion there can be infusion-related reactions. Recorded at the Myeloma 2016 meeting held in Boston, MA.